0002001011-24-000035.txt : 20240327 0002001011-24-000035.hdr.sgml : 20240327 20240327174759 ACCESSION NUMBER: 0002001011-24-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Todd C CENTRAL INDEX KEY: 0001392029 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 24792372 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-03-25 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001392029 Davis Todd C 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 1 1 0 0 Chief Executive Officer 0 Common Stock 2024-03-25 4 M 0 7448 46.2 A 111593 D Common Stock 2024-03-25 4 M 0 2855 67.24 A 114448 D Common Stock 2024-03-25 4 M 0 2156 68.51 A 116604 D Common Stock 2024-03-25 4 M 0 3556 66.19 A 120160 D Non-Qualified Stock Option (right to buy) 46.2 2024-03-25 4 M 0 7448 0.0 D 2032-06-10 Common Stock 7448 0 D Non-Qualified Stock Option (right to buy) 66.19 2024-03-25 4 M 0 3556 0.0 D 2029-06-06 Common Stock 3556 0 D Non-Qualified Stock Option (right to buy) 67.24 2024-03-25 4 M 0 2855 0.0 D 2031-06-04 Common Stock 2855 0 D Non-Qualified Stock Option (right to buy) 68.51 2024-03-25 4 M 0 2156 0.0 D 2030-06-10 Common Stock 2156 0 D This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023. This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis 2024-03-27